-
公开(公告)号：US20190092812A1
公开(公告)日：2019-03-28
申请号：US16025382
申请日：2018-07-02
申请人： H. Lee Moffitt Cancer Center And Research Institute, Inc. , University of South Florida , The Scripps Research Institute , Modulation Therapeutics
发明人： Lori Hazlehurst , Christoph Rader , Xiuling Li , Mark McLaughlin
IPC分类号： C07K7/06 , C07K14/705 , C07K1/00
摘要： The present invention concerns cyclic compounds, compositions comprising the cyclic compounds, linkers, a method of preparing a carrying agent:cyclic compound adduct, a method for treating disorders such as proliferation disorders (e.g., malignancies), bone deficiency diseases, and autoimmune diseases, and a method for suppressing the growth of, or inducing apoptosis in, cells (e.g., malignant cells).
-
公开(公告)号：US11078235B2
公开(公告)日：2021-08-03
申请号：US16025382
申请日：2018-07-02
申请人： H. Lee Moffitt Cancer Center And Research Institute, Inc. , University of South Florida , The Scripps Research Institute , Modulation Therapeutics
发明人： Lori Hazlehurst , Christoph Rader , Xiuling Li , Mark McLaughlin
IPC分类号： C07K7/06 , C07K7/08 , C07K14/705 , C07K1/00 , A61K38/00
摘要： The present invention concerns cyclic compounds, compositions comprising the cyclic compounds, linkers, a method of preparing a carrying agent:cyclic compound adduct, a method for treating disorders such as proliferation disorders (e.g., malignancies), bone deficiency diseases, and autoimmune diseases, and a method for suppressing the growth of, or inducing apoptosis in, cells (e.g., malignant cells).
-
公开(公告)号：US10011635B2
公开(公告)日：2018-07-03
申请号：US15024928
申请日：2014-09-26
申请人： H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. , UNIVERSITY OF SOUTH FLORIDA , THE SCRIPPS RESEARCH INSTITUTE , MODULATION THERAPEUTICS
发明人： Lori Hazlehurst , Christoph Rader , Xiuling Li , Mark McLaughlin
IPC分类号： A61K38/00 , C07K2/00 , C07K4/00 , C07K5/00 , C07K7/00 , C07K14/00 , C07K16/00 , C07K17/00 , C07K7/06 , C07K7/08 , C07K14/705 , C07K1/00
CPC分类号： C07K7/06 , A61K38/00 , C07K1/00 , C07K7/08 , C07K14/705 , C07K14/70596 , C07K2319/21 , C07K2319/30
摘要： The present invention concerns cyclic compounds, compositions comprising the cyclic compounds, linkers, a method of preparing a carrying agent:cyclic compound adduct, a method for treating disorders such as proliferation disorders (e.g., malignancies), bone deficiency diseases, and autoimmune diseases, and a method for suppressing the growth of, or inducing apoptosis in, cells (e.g., malignant cells).
-
公开(公告)号：US20180362583A1
公开(公告)日：2018-12-20
申请号：US16113869
申请日：2018-08-27
摘要： Integrin interaction inhibitors using a beta-turn promoter are described herein. These peptides are useful in treating cancer, such as multiple myeloma, by administering a therapeutically effective amount of the integrin interaction inhibitor. Data show that integrin interaction inhibitors act synergistically or additively interact with anti-proliferative agents such as doxorubicin, SAHA, arsenic trioxide, and etoposide.
-
公开(公告)号：US20150071918A1
公开(公告)日：2015-03-12
申请号：US14399291
申请日：2013-05-09
发明人： Mark McLaughlin , Lori Hazlehurst , Priyesh Jain , Michael F. Emmons , Anthony W. Gebhard , Rajesh R. Nair
IPC分类号： C07K7/06 , G01N33/574 , A61K47/48 , A61K38/08 , A61K45/06
CPC分类号： C07K7/06 , A61K38/00 , A61K38/08 , A61K45/06 , A61K47/54 , A61K47/545 , C07K7/56 , G01N33/574 , G01N2333/70585
摘要： The invention relates to novel cyclic compounds (cyclic peptides), linkers useful as beta-turn promoters in cyclic peptides, and methods for treatment of malignant cells in vitro or in vivo using one or more linear and cyclic peptides. The peptides can act as integrin interaction inhibitors and may be used in the treatment of cancers as monotherapies or in combination with other anti-cancer agents, such as proteasome inhibitors, inhibitors of autophagy, alkylating agents, MEK inhibitors, FAK/PYK2 inhibitors, and EGFR inhibitors. The invention further concerns a method of predicting the binding of a cyclic or linear HYD1 peptide to a cancer cell by assessing overexpression of biomarkers such as CD44, VLA-4 integrin, basigin, CD138 (syndecan 1), NCAM, ICAM1, ICAM3, and CD59. The invention further concerns a method of detecting one or more members of a complex comprising CD44, VLA-4 integrin, basigin, CD138 (syndecan 1), NCAM, ICAM1, ICAM3, and CD59, using a linear or cyclic HYD1 peptide bearing a detectable moiety.
摘要翻译： 本发明涉及新的环状化合物（环肽），用作环肽中的β-转角启动子的接头，以及使用一种或多种线性和环肽在体外或体内治疗恶性细胞的方法。 肽可以作为整联蛋白相互作用抑制剂，并且可以用于治疗癌症作为单一疗法或与其它抗癌剂如蛋白酶体抑制剂，自噬抑制剂，烷化剂，MEK抑制剂，FAK / PYK2抑制剂和 EGFR抑制剂。 本发明还涉及一种通过评估生物标志物如CD44，VLA-4整联蛋白，basigin，CD138（syndecan 1），NCAM，ICAM1，ICAM3等的过度表达来预测环状或线性HYD1肽与癌细胞的结合的方法。 CD59。 本发明还涉及使用具有可检测的线性或环状HYD1肽检测包含CD44，VLA-4整联蛋白，basigin，CD138（syndecan 1），NCAM，ICAM1，ICAM3和CD59的复合物的一个或多个成员的方法 部分。
-
公开(公告)号：US10059740B2
公开(公告)日：2018-08-28
申请号：US15165687
申请日：2016-05-26
摘要： Integrin interaction inhibitors using a beta-turn promoter are described herein. These peptides are useful in treating cancer, such as multiple myeloma, by administering a therapeutically effective amount of the integrin interaction inhibitor. Data show that integrin interaction inhibitors act synergistically or additively interact with anti-proliferative agents such as doxorubicin, SAHA, arsenic trioxide, and etoposide.
-
公开(公告)号：US12060438B2
公开(公告)日：2024-08-13
申请号：US16972558
申请日：2019-06-05
发明人： Mark McLaughlin , Lori Hazlehurst
摘要： Embodiments of the present disclosure generally relate to cyclic peptidomimetic compounds and methods for making the same. Other embodiments relate to a method of treating a disease by administering a pharmaceutically effective amount of a cyclic peptidomimetic disclosed herein, for example to treat cancer.
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.056 秒)
